Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients

European Journal of Clinical Investigation

Volumn 32, Issue SUPPL. 1, 2002, Pages 42-49

  Esposito B P ^a   Breuer, W ^a   Slotki, I ^b   Cabantchik, Z I ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Deferrioxamine; Dialysis; Free radicals; Iron; Oxidative stress; Transferrin

Indexed keywords

APOTRANSFERRIN; CHELATING AGENT; DEFEROXAMINE; FLUORESCEIN; FREE RADICAL; GALLIUM; IRON; OXALIC ACID; RHODAMINE; SCAVENGER; TRANSFERRIN; CARBOHYDRATE; IRON CHELATING AGENT;

ARTICLE; CARDIOVASCULAR RISK; CATALYSIS; CHELATION; DIALYSIS; DRUG CLEARANCE; DRUG FORMULATION; DRUG PROTEIN BINDING; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON KINETICS; IRON THERAPY; KIDNEY FAILURE; MOLECULAR WEIGHT; NONPHOTOCHEMICAL QUENCHING; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; SIDE EFFECT; ADOLESCENT; ADULT; AGED; ANEMIA; BLOOD; CHEMISTRY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFECT; INFUSION; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CARBOHYDRATES; CHEMISTRY, PHARMACEUTICAL; COHORT STUDIES; DEFEROXAMINE; FREE RADICALS; HUMANS; INFUSIONS, PARENTERAL; IRON; IRON CHELATING AGENTS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MOLECULAR WEIGHT; OXIDATIVE STRESS; RENAL DIALYSIS; TRANSFERRIN;

EID: 0038122576     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.0320s1042.x     Document Type: Article

References (34)

1. Mocks J, Franke W, Ehrner B, Scigalla P, Quarder O. Analysis of safety database for long-term epoetin-b treatment: a meta-analysis covering 3697 patients. In: Stein G, editor. Pathogenetic and Therapeutic Aspects of Chronic Renal Failure. New York, NY: Marcel Dekker; 1997, pp. 163-179.
2. Kooistra MP, Niemantsverdreit EC, van Es A, Mol-Beerman NM, Struyvenberg A, Marx JJM. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant 1998;13:82-8.
3. Silverberg DS, Blum M, Agbaria Z, Schwartz D, Zubkov A, Yachnin T, et al. Intravenous iron for the treatment of predialysis anemia. Kidney Int Suppl 1999;69:S79-85.
4. Eschbach JW. Clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997;30:S192-S240.
5. Besarab A, Frinak S, Yee J. An indistinct balance: the safety and efficacy of parenteral iron therapy. J Am Soc Nephrol 1999;10:2029-43.
6. NKF-DOQI. Clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Initiative. Am J Kidney Dis 1997;30:S192-S240.
7. Kernilde J-J, Folkert V, Mockrzycki M. Functional iron deficiency in hemodialysis patients with high ferritin levels. J Am Soc Nephrol 1998;9:253A.
8. Rooyakers TM, Stroes ESG, Kooistra MP, van Faassen EE, Hider RC, Rabelink TJ, et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction. Eur J Clin Invest 2002;32 (suppl 1):9-16.
9. Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin iron in disorders of iron metabolism. Transfusion Sci 2000;23:185-92.
10. Klausner RD, Rouault TA, Harford JB. Regulating the fate of mRNA. the control of cellular iron metabolism. Cell 1993;72:19-28.
11. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992;86:803-11.
12. Tielemans CL, Lenclud CM, Wens R, Collart FE, Dratwa M. Critical role of iron overload in the increases susceptibility of haemodialysis patients to bacterial infections: beneficial effects of desferrioxamine. Nephrol Dial Transplant 1989;4:883-7.
13. van-Dijk PC, Jager KJ, de-Charro F, Collart F, Cornet R, Dekker FW, et al. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 2001;16:1120-9.
14. Adamson JW, Eschbach JW. Erythropoietin for end-stage renal disease. N Engl J Med 1998;339:584-90.
15. Breuer W, Cabantchik ZI. A fluorescence-based one-step assay for serum non-transferrin bound iron (NTBI). Anal Biochem 2001;299:194-202.
16. Breuer W, Ermers MJJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI. Desferrioxamine-chelatable iron (DCI), a component of serum non-transferrin bound iron (NTBI) used for assessing chelation therapy. Blood 2001;97:792-8.
17. Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann NY Acad Sci 1964;119:758-68.
18. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Meth Enzymol 1990;186:1-85.
19. Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis 2001;37:564-72.
20. Halliwell B, Aruoma OI, Mufti G, Bomford A. Bleomycin detectable iron in serum from leukemic patients before and after chemjournalapy. FEBS Lett 1988;241:2020-204.
21. Gosriwatana I, Loreal O, Lu S, Brissot P, Porter J, Hider RC. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem 1999;273:212-20.
22. Kooistra MP, Kersting S, Gosriwatana I, Lu S, Hider RC, Marx JJM. Nontransferrin-bound iron in plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 2002;32 (suppl 1):36-41.
23. Evans PJ, Halliwell B. Measurement of iron and copper in biological systems: bleomycin and copper-phenanthroline assays. Meth Enzymol 1994;233:82-9.
24. Banyai S, Rainer V, Derfler K, Druml W, Hoerl W, Sunder-Plassman G. Bleomycin detectable free iron (BDI) is present in patients on intravenous (IV) iron therapy. J Am Soc Nephrol 1998;9:199A.
25. Sunder-Plassmann G, Horl WH. Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol Dial Transplant 1996;11:1797-802.
26. Zanen AL, Adrianssen HJ, van Bommel EF, Posthuma RTh, de Jong GM. Oversaturation of transferrin after intravenous ferric gluconate (Ferrlecit) in haemodialysis patients. Nephrol Dial Transplant 1996;11:820-4.
27. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 1992;42:1439-52.
28. Bailie GR, Johnson CA, Mason NA. Parenteral iron use in the management of anemia in end-stage renal disease patients. Am J Kidney Dis 2000;35:1-12.
29. Seligman PA, Schleicher RB. Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran. Clin Chem 1999;45:898-901.
30. Scheurmann E, Belwe V, BlaSeries C, Peschke B, Lenz T, Kaltwasser J. Parenteral iron causes increased peroxidation in hemodialysis patients. J Am Soc Nephrol 1997;7:251A.
31. United States Renal Data System. Causes of death in ESRD. Am J Kidney Dis 1999;34 (2 Suppl. 1):S87-94.
32. United States Renal Data System. Patient mortality and survival in ESRD. Am J Kidney Dis 1999;34 (2 Suppl. 1):S74-86.
33. Besarab A, Kline Bolton W, Brown K, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90.
34. Collins A, Ebben J, Ma J, Xia HIV. Iron dosing patterns and mortality. J Am Soc Nephrol 1998;9:205A.